89bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for 89bio Inc in the second quarter 2025?
89bio Inc recorded a cumulative net loss of $-450 million during 12 months ending in the second quarter 2025, resulting in a negative return on equity (ROE) of -94.48%.

Within the Major Pharmaceutical Preparations industry 231 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 2668 to 3171.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Equity Change	1.32 %	18.59 %	-25.27 %	-7.83 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-450	-387	-367	-289	-175
Return On Equity (TTM)	-94.48 %	-81.44 %	-81.38 %	-59.58 %	-35.42 %
ETNB's Total Ranking	# 3171	# 2668	# 2181	# 2647	# 2836
Equity (TTM) in Millions	522	605	401	378	515
Seq. Equity Change	-13.83 %	51.07 %	6 %	-26.57 %	0.86 %
Seq. Net Income Change	-	-	-	-	-

Back to ETNB Management Effectiveness >> ETNB's 5 Years Annual ROE >> Compare ETNB ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 232
Sector	# 515
Overall	# 3171

Return On Equity Statistics
High	Average	Low
48.08 %	-57.71 %	-123.39 %
(Jun 30 2020)		(Jun 30 2022)

News about 89bio Inc Return on Equity ROE

89bio Provides Business Update and Outlook for 2025

89bio Inc.: Strategic Moves Amidst Financial Challenges and Promising Clinical DevelopmentsOverview of Recent Developments 89bio Inc. has been capturing attention in the biotechnology sector as it navigates a challenging financial landscape while making strides in clinical research and talent acquisition. The company recently provided a business update and a fresh outlook for 2025, signaling its commitment to developing therapies for severe hypertriglyceridemia (SHTG). Key developments include the completion of patient enrollment in the pivotal Phase 3 ENTRUST trial, with topline data anticipated in the latter half of 2025. However, this optimistic clinical progress comes amid significant financial strains, as the company reported a cumulative net loss of $289 million for the twelve months ending in the third quarter of 2024, translating to a disheartening negative return on equity (ROE) of -59.58%. Financial Landscape 89bio s financial performance has placed it in stark contrast to its peers within the Major Pharmaceutical Preparations industry. Out of 169 comparable companies, 89bio s ROE remains significantly below the industry average. Despite a modest improvement in its overall ROE ranking—rising from 2852 to 2647 in one quarter—this change underscores the ongoing challenges the company faces. Financial health is crucial for investor confidence and can impede funding for its clinical trials, potentially hampering the company s growth trajectory.Strategic Workforce Expansion In a concerted effort to bolster its operational capabilities and attract top-tier talent, 89bio also announced a strategic induction plan, granting 48,000 stock options to a newly hired employee. This move comes as a significant component of the company’s 2023 Inducement Plan, reflecting an understanding of the competitive nature of the biopharmaceutical sector. Such initiatives are not uncommon in high-stakes environments where specialized expertise is paramount. By incentivizing skilled professionals during a pivotal phase, it aims to enhance its competencies while navigating through financial turbulence. This initiative aligns with recent upticks in share prices, suggesting that a favorable market perception could support the company’s strategic direction.

ETNB Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Equity in Millions	401	536	152	126	203
Y / Y Equity Change	-25.27 %	253.22 %	20.54 %	-37.94 %	125.65 %
Net Income in Millions	-367	-142	-102	-90	-49
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-91.59 %	-26.51 %	-67.2 %	-71.55 %	-24.39 %

Back to ETNB Management Effectiveness >> ETNB's 5 Years Annual ROE >> Compare ETNB ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ETNB's' Return on Equity at Yahoo Finance
ETNB's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ETNB's Competitors
Subscribers only: Roe for 89bio Inc 's Suppliers
Subscribers only: Return On Equity for ETNB's Customers

Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector

ROE

Date modified: 2026-09-08T15:11:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.